| Catalog No. | Size | Price (USD) |
| L10-12GG-10 | 10 µg | $545.05 |
| L10-12GG-50 | 50 µg | $1,715.12 |
| L10-12GG-500 | 500 µg | $4,025.65 |
General Information
| Validated applications | Kinase Assay |
| Formulation | Supplied as sterile 50 mM Tris-HCl, pH 7.5, 50-300mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25-1.0mM DTT, 0-0.1mM PMSF, 10-25% glycerol Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Shipping | Enzymes are highly recommended to be shipped at frozen temperature with dry ice. Shipment made at ambient temperature may seriously affect the activity of the ordered products. |
| Stability & Storage | Store product at –70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. |
| Purity | For specific information on a given lot, see related technical data sheet. |
| Activity | For specific information on a given lot, see related technical data sheet. |
| Protein Construction | Recombinant human LRRK2 (G2019S) (968-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. |
| Expressed Host | Baculovirus-Insect Cells |
| Species | Human |
| Molecule Mass | ~210 kDa |
| Technical Data Sheet by Lot # | F5060-7 R2698-7 T4109-2 Y4137-4 |
Synonyms: AURA17 Protein, Human; DARDARIN Protein, Human; DKFZp434H2111 Protein, Human; FLJ45829 Protein, Human; PARK8 Protein, Human; RIPK7 Protein, Human; ROCO2 Protein, Human
Background Information
| Full Name | leucine rich repeat kinase 2 |
| Description | Kinase activating missense mutations in leucine-rich repeat kinase 2 (LRRK2) are pathogenically linked to neurodegenerative Parkinson's disease (PD). LRRK2 harbors GTPase and kinase activities, two enzyme activities that play critical roles in the regulation of cellular signal transduction. Among the several LRRK2 pathogenic mutations, the most prevalent G2019S mutation increases its kinase activity when compared with the wild-type (WT), suggesting that LRRK2 kinase substrates are potential culprits of PD pathogenesis. Mutations in the LRRK2 gene are also found in immune-related disorders such as inflammatory bowel disease, tuberculosis, and leprosy. LRRK2 is highly expressed in immune cells and has been functionally linked to pathways pertinent to immune cell function, such as cytokine release, autophagy, and phagocytosis. Leucine-rich repeat kinase 2 (LRRK2) has been implicated in a wide range of cellular processes, including the catabolic pathways collectively described as autophagy. |
| References |
|
title: Azaindole inhibitors of wild-type and mutant forms of LRRK2
authors: Nathanael S. Gray; John Hatcher; ...; Namdoo Kim
date: 2025-04-15
cited_by_count: 0
techniques: Enzymatic Assay; Incubation; Inhibition; Kinase Assay; Positive Control; Serial Dilution
bioz_score: 93
title: Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
authors: Myungho Jung; Jungyeon Yun; ...; Daekwon Kim
date: 2025-03-04
cited_by_count: 0
techniques: Activity Assay; Purification
bioz_score: 93
title: Macrocyclic inhibitors of DYRK1A
authors: Nathanael S. Gray; John M. Hatcher; Hwangeun Choi
date: 2024-12-03
cited_by_count: 0
techniques: Enzymatic Assay; Inhibition
bioz_score: 93
MDSD
